Back to search

Article

Evaluation of treatment efficacy of tyrosine kinase inhibitors in rare single EGFR Exon 21 L861Q mutation; single center experience.

2021-12-13

Abstract excerpt

<h4>Aim: </h4> Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC).We aimed to compare the first generation erlotinib treatment with the second generation afatinib treatment in patients with Non-small Cell Lung Cancer (NSCLC) with Epidermal growth factor receptor (EGFR) Exon 21 L861Q mutation. Patients and Methods: Progression-fr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
794ee686-9898-57d4-aacf-b19da58ec7ad
DOI
10.21203/rs.3.rs-1161782/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluation of treatment efficacy of tyrosine kinase inhibitors in rare single EGFR Exon 21 L861Q mutation; single center experience.DOI 10.21203/rs.3.rs-1161782/v1
Treatment Patterns and Survival Outcomes in a Real-World Cohort of 263 Patients with EGFR L858R-Mutant Non-Small Cell Lung Cancer: Focus on EGFR-TKI Selection.Semantic proximity
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.Semantic proximity
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief ReportSemantic proximity
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.Semantic proximity
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatmentSemantic proximity
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.Semantic proximity
Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report.Semantic proximity
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.Semantic proximity
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.Semantic proximity
Outcomes of Afatinib in Non-small Cell Lung Cancer Patients Harboring Uncommon Epidermal Growth Factor Receptor MutationsSemantic proximity
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.Semantic proximity
Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.Semantic proximity
Select a neighboring publication to make it the new centre.